Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 6-month, Phase II, Double-masked, Multicenter, Randomized, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Topical Administration of Two Concentrations of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy

NCT01319487 is registered in ClinicalTrials.gov with Fovea Pharmaceuticals SA as lead sponsor.

NCT NCT01319487
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01319487 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 6-month, Phase II, Double-masked, Multicenter, Randomized, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Topical Administration of Two Concentrations of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy
Lead sponsor
Fovea Pharmaceuticals SA
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2011
Completion date
June 30, 2012
Enrollment
267 (actual)
Sites
65

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema